HYFT
MindWalk·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HYFT
Mindwalk Holdings Corp.
A"bio native AI"platform company transforming from wet experimental services
Industrious 823 Congress Ave Suite 300 Austin, Texas 78701, United States
--
MindWalk Holdings Corp. continued to operate on September 2, 2016 under the Business Corporations Act. On December 21, 2016, the company changed its name to "Immunoprecise Antibodies Ltd.". The company is an innovation-driven technology platform company that supports its partners in pharmaceutical and biotechnology companies to explore and develop novel therapeutic antibodies against various disease targets. The company's goal is to change the traditional, multi-supplier product development model, bring innovative high-throughput technologies to its partners, combine the advantages of multiple antibody libraries with the company's therapeutic antibody discovery technology portfolio, develop antibodies with broad epitope coverage, multiple antibody forms, valence codes and sizes, and discover antibodies against multiple/rare epitopes.
Earnings Call
Q1/2026
Estimate EPS-0.04
Actual EPS-0.05056
Estimate Revenue4.28M
Actual Revenue2.28M
MindWalk's Q1 2026: Contradictions Emerge on European Divestiture, GLP-1 Monetization, and AI-Wet Lab Integration
Sep 15,2025 10:38
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
HYFT has released its 2025 Q4 earnings. EPS was reported at -0.04, versus the expected -0.02, missing expectations. The chart below visualizes how HYFT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HYFT has released its 2026 Q1 earnings report, with revenue of 2.28M, reflecting a YoY change of 27.46%, and net profit of -2.14M, showing a YoY change of 26.21%. The Sankey diagram below clearly presents HYFT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
